A Phase 3 interventional study of V116 and QIV in Pneumonia, Pneumococcal, sponsored by Merck Sharp & Dohme LLC. Completed at 56 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.
Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 10th registered.
44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.
Browse Pneumonia, Pneumococcal studies →None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →
Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,080 is above the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.
Median enrollment 431 across the 11 interventional studies, 782 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 8 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 4 studies filed under Pneumonia, Pneumococcal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered concomitantly with Quadrivalent Influenza Vaccine (QIV) compared with V116 administered sequentially with QIV. The primary hypotheses state that immune responses to V116 and to QIV are non-inferior when administered concomitantly as compared with sequential administration as measured by serotype-specific opsonophagocytic activity (OPA) for V116 and hemagglutination inhibition (HAI) geometric mean titers (GMTs) for QIV, at 30 days postvaccination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
Biological: V116 · Biological: QIV · Biological: Matching Placebo for V116
Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V116 on Day 30
Biological: V116 · Biological: QIV · Biological: Matching Placebo for V116
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Single 0.5 mL IM injection
Single 0.5 mL of sterile saline IM injection
Number of Participants With Solicited Injection-site Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included erythema, pain, and swelling.
Time frame: Up to 5 days post-vaccination
Number of Participants With Solicited Systemic AEs
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include fatigue, headache, myalgia, and pyrexia.
Time frame: Up to 5 days post-vaccination
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized.
Time frame: Up to ~6 months postvaccination with V116
Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) Responses
OPA for the serotypes in V116 were determined using a multiplexed opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs (GMTs) (estimated) and GMT ratios with 95% CIs were calculated using a constrained longitudinal data analysis (cLDA) model utilizing data from both vaccination groups. Per the statistical analysis plan, the only CIs calculated were the between-group CIs (for the GMT ratios); within-group CIs were not calculated.
Time frame: 30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)
GMT of Influenza Strain-specific Hemagglutination Inhibition (HAI)
GMTs for the 4 strains contained in QIV vaccine were determined using an HAI assay.
Time frame: Day 30
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)
The GMCs of serotype-specific IgG for the serotypes contained in V116 were determined using a pneumococcal electrochemiluminescence (Pn ECL) assay.
Time frame: 30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)
Geometric Mean Fold Rise (GMFR) Ratio of Serotype-specific OPA
OPA for the serotypes in V116 were determined using a MOPA. GMFR ratio is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.
Time frame: Baseline (Day 1 for the concomitant group and Day 30 for the sequential group) and Postvaccination (Day 30 for the concomitant group and Day 59 for the sequential group)
GMFR Ratio of Serotype-specific IgG
GMFR ratios for the serotype-specific IgG in V116 were determined using a Pn ECL.
Time frame: Baseline (Day 1 for the concomitant group and Day 30 for the sequential group) and Postvaccination (Day 30 for the concomitant group and Day 59 for the sequential group)
GMFR in Influenza Strain-specific HAI
Activity for the 4 strains contained in QIV vaccine was determined using an HAI assay. GMFR is GMT 30 days after vaccination / GMT at Baseline.
Time frame: Day 1 (Baseline) and Day 30 (Postvaccination)
Percentage of Participants Who Seroconvert for Influenza Strain-specific HAI Titer ≥1:40
The percentage of participants with seroconversion is presented. Activity for the 4 strains contained in QIV vaccine was determined using an HAI assay.
Time frame: Day 30
This study was conducted at 56 centers in the United States.
| Milestone | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| Started | 540 | 540 |
| Vaccinated at visit 1 | 536 | 536 |
| Vaccinated at visit 1 | 534 | 0 |
| Vaccinated at visit 1 | 0 | 535 |
| Vaccinated at visit 3 | 522 | 0 |
| Vaccinated at visit 3 | 0 | 518 |
| Completed | 510 | 507 |
| Not completed | 30 | 33 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Lost to follow-up | 17 | 15 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Randomized by mistake without study treatment | 0 | 1 |
| Withdrew: Withdrawal by subject | 12 | 12 |
| Withdrew: Not reported | 0 | 2 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included erythema, pain, and swelling.
| Participants | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| Number of Participants With Solicited Injection-site Adverse Events (AEs) | 317 | 314 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include fatigue, headache, myalgia, and pyrexia.
| Participants | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| Number of Participants With Solicited Systemic AEs | 219 | 224 |
A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized.
| Participants | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) | 0 | 1 |
OPA for the serotypes in V116 were determined using a multiplexed opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs (GMTs) (estimated) and GMT ratios with 95% CIs were calculated using a constrained longitudinal data analysis (cLDA) model utilizing data from both vaccination groups. Per the statistical analysis plan, the only CIs calculated were the between-group CIs (for the GMT ratios); within-group CIs were not calculated.
| Titers | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| 3 | 209.2 (NA to NA) | 250.1 (NA to NA) |
| 6A | 2056.4 (NA to NA) | 2608.2 (NA to NA) |
| 7F | 2399.2 (NA to NA) | 3275.4 (NA to NA) |
| 8 | 1508.9 (NA to NA) | 2135.7 (NA to NA) |
| 9N | 5075.6 (NA to NA) | 7566.6 (NA to NA) |
| 10A | 3033.6 (NA to NA) | 3966.2 (NA to NA) |
| 11A | 2576.3 (NA to NA) | 4051.1 (NA to NA) |
| 12F | 1869.9 (NA to NA) | 2449.5 (NA to NA) |
| 15A | 4670.6 (NA to NA) | 6559.7 (NA to NA) |
| 15C | 3426.0 (NA to NA) | 4832.6 (NA to NA) |
| 16F | 5371.5 (NA to NA) | 7757.2 (NA to NA) |
| 17F | 5783.8 (NA to NA) | 7924.3 (NA to NA) |
| 19A | 1830.1 (NA to NA) | 2453.3 (NA to NA) |
| 20A | 5172.8 (NA to NA) | 6986.9 (NA to NA) |
| 22F | 3194.9 (NA to NA) | 4158.2 (NA to NA) |
| 23A | 3358.2 (NA to NA) | 4319.9 (NA to NA) |
| 23B | 934.3 (NA to NA) | 1664.5 (NA to NA) |
| 24F | 2996.5 (NA to NA) | 4143.1 (NA to NA) |
| 31 | 2997.4 (NA to NA) | 4390.6 (NA to NA) |
| 33F | 9032.5 (NA to NA) | 10765.1 (NA to NA) |
| 35B | 7701.4 (NA to NA) | 9940.2 (NA to NA) |
GMTs for the 4 strains contained in QIV vaccine were determined using an HAI assay.
| Titers | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| A/H1N1 | 268.23 (NA to NA) | 325.06 (NA to NA) |
| A/H3N2 | 128.07 (NA to NA) | 163.06 (NA to NA) |
| B/Victoria | 70.02 (NA to NA) | 85.66 (NA to NA) |
| B/Yamagata | 31.80 (NA to NA) | 35.86 (NA to NA) |
The GMCs of serotype-specific IgG for the serotypes contained in V116 were determined using a pneumococcal electrochemiluminescence (Pn ECL) assay.
| µg/mL | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| 3 | 0.60 (NA to NA) | 0.66 (NA to NA) |
| 6A | 3.34 (NA to NA) | 3.58 (NA to NA) |
| 7F | 3.91 (NA to NA) | 5.01 (NA to NA) |
| 8 | 6.84 (NA to NA) | 8.38 (NA to NA) |
| 9N | 4.99 (NA to NA) | 5.64 (NA to NA) |
| 10A | 8.45 (NA to NA) | 10.70 (NA to NA) |
| 11A | 4.83 (NA to NA) | 5.84 (NA to NA) |
| 12F | 1.10 (NA to NA) | 1.31 (NA to NA) |
| 15A | 8.83 (NA to NA) | 11.77 (NA to NA) |
| 15C | 7.13 (NA to NA) | 8.39 (NA to NA) |
| 16F | 1.93 (NA to NA) | 2.32 (NA to NA) |
| 17F | 9.69 (NA to NA) | 11.44 (NA to NA) |
| 19A | 6.41 (NA to NA) | 7.91 (NA to NA) |
| 20A | 13.57 (NA to NA) | 16.52 (NA to NA) |
| 22F | 3.13 (NA to NA) | 3.34 (NA to NA) |
| 23A | 3.30 (NA to NA) | 3.87 (NA to NA) |
| 23B | 4.24 (NA to NA) | 4.94 (NA to NA) |
| 24F | 5.72 (NA to NA) | 6.71 (NA to NA) |
| 31 | 2.50 (NA to NA) | 2.96 (NA to NA) |
| 33F | 9.09 (NA to NA) | 11.26 (NA to NA) |
| 35B | 15.73 (NA to NA) | 18.57 (NA to NA) |
OPA for the serotypes in V116 were determined using a MOPA. GMFR ratio is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.
| Ratio | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| 3 | 5.2 (4.6 to 5.9) | 6.7 (5.9 to 7.6) |
| 6A | 9.4 (8.0 to 11.1) | 13.2 (11.0 to 15.8) |
| 7F | 8.1 (6.8 to 9.6) | 9.8 (8.1 to 11.9) |
| 8 | 9.6 (8.0 to 11.6) | 10.9 (9.0 to 13.3) |
| 9N | 6.2 (5.3 to 7.4) | 8.2 (6.9 to 9.6) |
| 10A | 10.4 (8.7 to 12.6) | 11.1 (9.2 to 13.4) |
| 11A | 13.0 (10.7 to 15.9) | 15.2 (12.4 to 18.7) |
| 12F | 37.4 (30.8 to 45.5) | 46.8 (37.7 to 58.0) |
| 15A | 7.6 (6.4 to 9.1) | 8.9 (7.3 to 11.0) |
| 15C | 25.0 (20.5 to 30.4) | 30.2 (24.5 to 37.3) |
| 16F | 9.9 (8.6 to 11.4) | 11.9 (10.3 to 13.7) |
| 17F | 10.4 (8.8 to 12.4) | 15.1 (12.8 to 18.0) |
| 19A | 3.6 (3.2 to 4.2) | 5.2 (4.5 to 6.1) |
| 20A | 6.7 (5.7 to 7.7) | 8.5 (7.3 to 9.9) |
| 22F | 13.7 (11.2 to 16.8) | 16.9 (13.6 to 20.9) |
| 23A | 17.0 (14.0 to 20.8) | 25.5 (20.4 to 31.8) |
| 23B | 42.9 (35.4 to 52.0) | 60.9 (48.9 to 75.9) |
| 24F | 31.6 (26.1 to 38.3) | 33.2 (27.3 to 40.5) |
| 31 | 29.8 (24.5 to 36.2) | 40.3 (32.5 to 49.9) |
| 33F | 5.5 (4.7 to 6.4) | 6.3 (5.3 to 7.4) |
| 35B | 5.5 (4.7 to 6.4) | 6.3 (5.3 to 7.4) |
GMFR ratios for the serotype-specific IgG in V116 were determined using a Pn ECL.
| Ratio | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| 3 | 3.6 (3.3 to 4.0) | 4.1 (3.7 to 4.6) |
| 6A | 7.8 (6.9 to 8.9) | 8.4 (7.3 to 9.7) |
| 7F | 5.6 (5.0 to 6.4) | 7.2 (6.3 to 8.2) |
| 8 | 7.1 (6.2 to 8.1) | 8.7 (7.5 to 10.1) |
| 9N | 8.0 (6.9 to 9.2) | 9.0 (7.8 to 10.5) |
| 10A | 9.3 (8.1 to 10.6) | 11.4 (9.9 to 13.1) |
| 11A | 5.7 (5.1 to 6.4) | 7.2 (6.3 to 8.1) |
| 12F | 6.9 (6.0 to 8.0) | 7.9 (6.8 to 9.1) |
| 15A | 14.2 (12.3 to 16.4) | 19.5 (16.8 to 22.5) |
| 15C | 11.0 (9.6 to 12.6) | 12.3 (10.6 to 14.2) |
| 16F | 11.1 (9.8 to 12.6) | 13.4 (11.8 to 15.2) |
| 17F | 10.9 (9.5 to 12.5) | 13.2 (11.5 to 15.3) |
| 19A | 3.0 (2.7 to 3.4) | 3.9 (3.5 to 4.5) |
| 20A | 7.4 (6.5 to 8.4) | 8.9 (7.7 to 10.2) |
| 22F | 8.2 (7.1 to 9.4) | 9.0 (7.8 to 10.3) |
| 23A | 15.5 (13.6 to 17.6) | 17.3 (15.0 to 20.0) |
| 23B | 10.2 (8.9 to 11.6) | 10.9 (9.4 to 12.6) |
| 24F | 20.2 (17.4 to 23.4) | 23.5 (20.3 to 27.3) |
| 31 | 12.6 (11.2 to 14.2) | 15.3 (13.5 to 17.3) |
| 33F | 5.1 (4.5 to 5.7) | 6.2 (5.4 to 7.1) |
| 35B | 12.3 (10.9 to 13.9) | 14.9 (13.0 to 17.1) |
Activity for the 4 strains contained in QIV vaccine was determined using an HAI assay. GMFR is GMT 30 days after vaccination / GMT at Baseline.
| Ratio | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| A/H1N1 | 4.5 (3.9 to 5.2) | 5.7 (4.9 to 6.7) |
| A/H3N2 | 5.6 (5.0 to 6.3) | 7.1 (6.3 to 8.1) |
| B/Victoria | 3.6 (3.3 to 4.0) | 4.5 (4.0 to 5.1) |
| B/Yamagata | 1.9 (1.8 to 2.1) | 2.2 (2.1 to 2.4) |
The percentage of participants with seroconversion is presented. Activity for the 4 strains contained in QIV vaccine was determined using an HAI assay.
| Percentage of Participants | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| A/H1N1 | 47.1 (42.6 to 51.7) | 55.6 (51.0 to 60.1) |
| A/H3N2 | 63.8 (59.4 to 68.1) | 68.3 (63.9 to 72.4) |
| B/Victoria | 52.3 (47.7 to 56.8) | 54.1 (49.6 to 58.7) |
| B/Yamagata | 23.3 (19.6 to 27.4) | 29.9 (25.8 to 34.2) |
Collected over Up to ~6 months postvaccination with V116. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Concomitant Group (V116 + QIV Followed by Placebo) | 1/540 (0.2%) | 10/534 (1.9%) | 362/534 (67.8%) |
| Sequential Group (Placebo + QIV Followed by V116) | 2/540 (0.4%) | 17/535 (3.2%) | 348/535 (65%) |
| Event | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/534 | 0/535 |
| Blood loss anaemiaBlood and lymphatic system disorders | 1/534 | 0/535 |
| Atrial fibrillationCardiac disorders | 1/534 | 1/535 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/534 | 0/535 |
| PancreatitisGastrointestinal disorders | 1/534 | 0/535 |
| DiverticulitisInfections and infestations | 1/534 | 0/535 |
| InfluenzaInfections and infestations | 1/534 | 0/535 |
| Wound infectionInfections and infestations | 1/534 | 0/535 |
| Ankle fractureInjury, poisoning and procedural complications | 1/534 | 0/535 |
| HypokalaemiaMetabolism and nutrition disorders | 1/534 | 0/535 |
| Event | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) |
|---|---|---|
| Injection site painGeneral disorders | 310/534 | 303/535 |
| FatigueGeneral disorders | 162/534 | 175/535 |
| HeadacheNervous system disorders | 109/534 | 120/535 |
| MyalgiaMusculoskeletal and connective tissue disorders | 74/534 | 80/535 |
| Injection site swellingGeneral disorders | 68/534 | 66/535 |
| Injection site erythemaGeneral disorders | 63/534 | 60/535 |
All vaccinated participants are included.
| Age, Continuous(years) | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) | Total |
|---|---|---|---|
| Mean | 64.2 ± 8.4 | 64.2 ± 8.4 | 64.2 ± 8.4 |
| Sex: Female, Male(Participants) | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) | Total |
|---|---|---|---|
| Female | 297 | 287 | 584 |
| Male | 239 | 249 | 488 |
| Ethnicity (NIH/OMB)(Participants) | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) | Total |
|---|---|---|---|
| Hispanic or Latino | 127 | 125 | 252 |
| Not Hispanic or Latino | 403 | 409 | 812 |
| Unknown or Not Reported | 6 | 2 | 8 |
| Race (NIH/OMB)(Participants) | Concomitant Group (V116 + QIV Followed by Placebo) | Sequential Group (Placebo + QIV Followed by V116) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 4 | 5 |
| Asian | 3 | 10 | 13 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 107 | 101 | 208 |
| White | 410 | 412 | 822 |
| More than one race | 13 | 8 | 21 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2022 to primary completion in Jun 2023, 8 months.
Results were first posted in Sep 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine